Drugs / Zopiclone
Zopiclone
also known as
Imovane · Amoban · NSC-758463 · RP-27267 · Zileze 3.75 · Zileze 7.5 · Zimovane · Zimovane ls · +1 more
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01489982 | Jan 2011 → Dec 2012 | Parkinson disease, insomnia | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 18 trials · 2 met primary · 1 missed | ||||||
| Phase 1 | NCT06219902 | Jan → Apr 2024 | — | Bayer | Completed | Met primary |
| Phase 1 | NCT05819710 | May → Aug 2023 | — | Taisho Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 1 | NCT04696952 | Jan 2021 → Jan 2022 | — | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04451187 | Jul 2020 → Mar 2023 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03892902 | Mar → Oct 2019 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03632408 | Sep 2018 → May 2019 | alcohol-related disorders | Petri Vainio | Unknown | No outcome recorded |
| Phase 1 | NCT02583451 | Nov 2015 → Jan 2017 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00319215 | Mar → Jul 2006 | insomnia | Utrecht Institute for Pharmaceutical Sciences | Completed | Missed primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT03339583 | Apr 2015 → Mar 2017 | insomnia | I.M. Sechenov First Moscow State Medical University | Completed | No outcome recorded |
| Phase 34 trials · 2 missed | ||||||
| Phase 3 | NCT03075241 | Oct 2016 → Apr 2020 | Alzheimer disease, insomnia | Brasilia University Hospital | Completed | Missed primary |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT01369576 | May 2011 → May 2014 | obstructive sleep apnea syndrome | OSR Medical Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00699608 | Jul → Oct 2008 | sleep disorder, initiating and maintaining sleep | GlaxoSmithKline | Completed | Missed primary |
| Phase 43 trials · 1 missed | ||||||
| Phase 4 | NCT02820441 | May 2016 → Sep 2017 | cardiac ventricle disorder, central sleep apnea syndrome | University Hospital, Grenoble | Terminated | No outcome recorded |
| Phase 4 | NCT01549691 | Mar 2012 → Apr 2013 | anxiety | University Hospital, Angers | Completed | Missed primary |
| Phase 4 | NCT00295386 | Jan 2004 → Jan 2006 | insomnia | University of Bergen | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT03351439 | Apr 2018 → Sep 2021 | chronic pain syndrome | Western University, Canada | Completed | No outcome recorded |
| — | NCT01257165 | Aug → Dec 2012 | — | St. Olavs Hospital | Withdrawn | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 1 | NCT01311882 Comparator | Apr → Nov 2011 | insomnia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01106859 Comparator | Jun → Sep 2010 | insomnia | Transcept Pharmaceuticals | Completed | Missed primary |
| Phase 1 | NCT00798395 Comparator | Oct 2007 → Sep 2008 | mental disorder, sleep disorder, initiating and maintaining sleep | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02732912 Background | Nov 2016 → Feb 2017 | — | Oxford University Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 3 | NCT01100164 Comparator | Mar 2011 → Mar 2012 | insomnia | Eurofarma Laboratorios S.A. | Completed | Met primary |
| Phase 3 | NCT00237497 Comparator | Jul 2005 → Oct 2006 | — | Takeda | Completed | No outcome recorded |
| Phase 4 | NCT02807922 Comparator | Nov 2016 → Jul 2021 | insomnia | St. Olavs Hospital | Completed | No outcome recorded |
| — | NCT00888342 Comparator | May 2009 → Jul 2011 | cardiac rhythm disease, chronic obstructive pulmonary disease, respiratory underresponsiveness to hypoxia and hypercapnia | LHL Helse | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 29 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zopiclone | “The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer's disease: a randomized, triple-blind, placebo-controlled trial.” PMID 34635802 ↗ Oct 2021 |
| Known as | Amoban | ChEMBL registry synonym — accepted as the source's own label CHEMBL135400 ↗ |
| Known as | Imovane | “The primary objective of the study is to determine whether eszopiclone (Eurofarma) is non-inferior to the reference drug zopiclone (Imovane®, Sanofi-Aventis) in the treatment...” NCT01100164 ↗1“this will either be a medication called desipramine (also called Doxepin), or zopiclone (also called Imovane).” NCT01489982 ↗ |
| Known as | NSC-758463 | ChEMBL registry synonym — accepted as the source's own label CHEMBL135400 ↗ |
| Known as | RP-27267 | ChEMBL registry synonym — accepted as the source's own label CHEMBL135400 ↗ |
| Known as | Zileze 3.75 | ChEMBL registry synonym — accepted as the source's own label CHEMBL135400 ↗ |
| Known as | Zileze 7.5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL135400 ↗ |
| Known as | Zimovane | ChEMBL registry synonym — accepted as the source's own label CHEMBL135400 ↗ |
| Known as | Zimovane ls | ChEMBL registry synonym — accepted as the source's own label CHEMBL135400 ↗ |
| Known as | Zopiclona | ChEMBL registry synonym — accepted as the source's own label CHEMBL135400 ↗ |
| Action | Activate | “two selective GABA-A agonists, zopiclone and eszopiclone” PMID 26872077 ↗ Jan 2016 |
| Modality | Small molecule | — CHEMBL135400 ↗ |
| Route | Oral | “Zopiclone 7.5 mg, tablets, orally, once daily for up to 28 nights.” NCT00237497 ↗ |